Only a little over a year after its founding, Anaveon has completed a CHF35m series A financing to advance selective interleukin-2 (IL-2) receptor agonists from preclinical studies into the clinic.
Set up by two immunotherapy experts, Onur Boyman, professor and chair in the department of immunology at the University of...